Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled study of regorafenib in metastatic bone sarcomas
2013-003910-42Phase 2Active
- Sponsor
- Unicancer
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in bone cancer, osteosarcoma (OS), Ewing sarcoma and 1 more comparing Regorafenib with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Aug 2015; status: active.
02
Drugs
regorafenib
03
Conditions
bone cancerosteosarcoma (OS)Ewing sarcomachondrosarcoma
Beyond the preview
Go deeper on 2013-003910-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003910-42.